- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D o...
SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gast...
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional inv...
Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-gene...
Antengene Corporation Limited, a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing fir...
“Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry,” said Dani...
New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partne...
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in Europe Omlyclo™ 300 mg/2ml prefilled syringe (PFS) p...
-Galux, a South Korean biotech pioneering AI-driven protein therapeutics design, announced new experimental findings demonstrating that its AI protein de...
LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...
Patent expands MEAI’s global intellectual property protection as Clearmind advances clinical development and commercialization plans Clearmind Med...
Samsung Bioepis will assume full commercial responsibility for BYOOVIZ®(ranibizumab) upon full transition of Biogen’s commercializa...
SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facili...
Members of Management and Business Development will be at BioProcess International Asia in Kyoto, Japan, October 20-22, 2025 Company will introduce th...
© 2025 Biopharma Boardroom. All Rights Reserved.
